Dual Diagnosis Clinical Trial
Official title:
Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use
This trial examines the efficacy of cannabidiol (CBD) versus risperidone for treatment of psychosis in patients with non affective-psychosis and lifetime use of cannabis.
People with psychosis and comorbid cannabis use are particularly difficult to treat because cannabis use worsens psychotic symptoms and increases the risk that a first-episode psychosis will progress to schizophrenia. It is the THC (tetrahydrocannabinol) content in cannabis that aggravates psychotic symptoms whereas the CBD content has potential therapeutic effects. This trial investigates treatment with CBD (without THC) versus risperidone (an antipsychotic agent) in people with psychosis and lifetime use of cannabis. We hypothesize that CBD will ameliorate psychotic symptoms and reduce the frequency of cannabis use to a larger extent than risperidone. Sleep disturbances are often a limiting factor in the treatment of psychosis, and it is also examined how CBD affects objective and subjective sleep quality as well as circadian rest-activity cycles. Based on previous studies investigating CBD as monotherapy in patients with schizophrenia, it is expected that CBD will be associated with fewer adverse events than risperidone. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05054738 -
CRP and S&A for Inpatient Veterans
|
N/A | |
| Completed |
NCT02233738 -
Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services
|
N/A | |
| Completed |
NCT02192931 -
A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users
|
Phase 4 | |
| Completed |
NCT00970372 -
Dual-Diagnosis and Compulsory Treatment
|
N/A | |
| Completed |
NCT02520271 -
Ostrobothnia Depression Study (ODS). A Naturalistic Follow-up Study on Depression and Related Substance Use Disorders
|
N/A | |
| Completed |
NCT00498550 -
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
|
Phase 4 | |
| Not yet recruiting |
NCT06315660 -
VR Based Therapy to Treat Anxiety in Dual Diagnosis
|
N/A | |
| Recruiting |
NCT06311838 -
Building Social and Structural Connections for the Prevention of Opioid Use Disorder Among Youth Experiencing Homelessness
|
N/A | |
| Completed |
NCT00706901 -
Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans
|
N/A | |
| Terminated |
NCT00169026 -
Alcoholism and Schizophrenia: Effects of Clozapine
|
Phase 4 | |
| Completed |
NCT01639872 -
Clozapine for Cannabis Use in Schizophrenia
|
Phase 4 | |
| Active, not recruiting |
NCT02404662 -
Trial of Supportive Text Messages for Patients With Alcohol Use Disorder and a Co-morbid Depression
|
N/A | |
| Completed |
NCT00218582 -
Effectiveness of Self-Help for Dually-Diagnosed Persons - 1
|
Phase 1/Phase 2 | |
| Completed |
NCT01964404 -
Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
|
Phase 1 | |
| Completed |
NCT00105768 -
Effectiveness of Advisor-Teller Money Manager
|
Phase 1/Phase 2 | |
| Completed |
NCT01514630 -
Creatine as a Treatment Option for Depression in Methamphetamine Using Females
|
Phase 4 | |
| Terminated |
NCT02189915 -
Open-Label Creatine Study for Female Meth Users
|
N/A | |
| Completed |
NCT02082678 -
Ondansetron for Bipolar Disorder and Alcohol Use Disorders
|
Phase 4 | |
| Completed |
NCT01411085 -
Risperidone and Desipramine in Alcohol Use and Schizophrenia
|
Phase 2 | |
| Completed |
NCT00946348 -
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
|
Phase 1 |